Mereo BioPharma Group Statistics
Total Valuation
MREO has a market cap or net worth of $389.36 million. The enterprise value is $325.24 million.
| Market Cap | 389.36M |
| Enterprise Value | 325.24M |
Important Dates
The last earnings date was Wednesday, March 27, 2024, after market close.
| Earnings Date | Mar 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MREO has 140.06 million shares outstanding.
| Shares Outstanding | 140.06M |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 61.42% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 38.94 |
| Forward PS | 4.37 |
| PB Ratio | 6.18 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 32.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.72, with a Debt / Equity ratio of 0.12.
| Current Ratio | 6.72 |
| Quick Ratio | n/a |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.86 |
Financial Efficiency
Return on equity (ROE) is -57.80% and return on invested capital (ROIC) is -50.30%.
| Return on Equity (ROE) | -57.80% |
| Return on Assets (ROA) | -41.00% |
| Return on Capital (ROIC) | -50.30% |
| Revenue Per Employee | $303,030 |
| Profits Per Employee | -$892,909 |
| Employee Count | 33 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.26M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +167.31% in the last 52 weeks. The beta is 0.78, so MREO's price volatility has been lower than the market average.
| Beta (1Y) | 0.78 |
| 52-Week Price Change | +167.31% |
| 50-Day Moving Average | 3.29 |
| 200-Day Moving Average | 2.28 |
| Relative Strength Index (RSI) | 39.99 |
| Average Volume (30 Days) | 1,525,775 |
Short Selling Information
| Short Interest | 2.33M |
| Short Previous Month | 2.19M |
| Short % of Shares Out | 2.01% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.78 |
Income Statement
In the last 12 months, MREO had revenue of $10.00 million and -$29.47 million in losses. Loss per share was -$0.25.
| Revenue | 10.00M |
| Gross Profit | 9.25M |
| Operating Income | -35.40M |
| Pretax Income | -38.97M |
| Net Income | -29.47M |
| EBITDA | -34.06M |
| EBIT | -35.38M |
| Loss Per Share | -$0.25 |
Balance Sheet
The company has $71.54 million in cash and $7.42 million in debt, giving a net cash position of $64.12 million or $0.46 per share.
| Cash & Cash Equivalents | 71.54M |
| Total Debt | 7.42M |
| Net Cash | 64.12M |
| Net Cash Per Share | $0.46 |
| Equity / Book Value | 62.96M |
| Book Value Per Share | 0.45 |
| Working Capital | 67.62M |
Cash Flow
| Operating Cash Flow | -26.33M |
| Capital Expenditures | n/a |
| Free Cash Flow | -26.33M |
| FCF Per Share | -$0.20 |
Margins
Gross margin is 92.52%, with operating and profit margins of -354.03% and -294.66%.
| Gross Margin | 92.52% |
| Operating Margin | -354.03% |
| Pretax Margin | -389.69% |
| Profit Margin | -294.66% |
| EBITDA Margin | -340.57% |
| EBIT Margin | -353.79% |
| FCF Margin | -263.28% |
Dividends & Yields
MREO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.11% |
| Shareholder Yield | -21.11% |
| Earnings Yield | -7.57% |
| FCF Yield | -6.76% |
Analyst Forecast
The average price target for MREO is $6.50, which is 133.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.50 |
| Price Target Difference | 133.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 55.93% |
| EPS Growth Forecast (5Y) | -24.04% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MREO has an Altman Z-Score of 2.6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.6 |
| Piotroski F-Score | 3 |